NEW—Interim analysis of Russian #COVID19#vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS
Cancer mortality, healthcare expenditure & access to medicines should be the focus today for successful cancer care in the future. Read more in this blog by Deepak Khanna @dkkhanna65@MSDInvents Senior VP and Regional President Oncology https://t.co/aOzU08MSxv #TeamForHope
I am Solange Peters, ESMO President Elect, and I will work hard to secure access to optimal care for #cancer patients, no matter where in the world they live. #WorldCancerDay#IAmAndIWill https://t.co/gXucYDvEzj @peters_solange@uicc
It's time to reflect on 2018. This video summarizes my Top 5 Most Influential Lung Cancer Trials in 2018.
https://t.co/wPbojQO4Cb
Mostly immunotherapy, but not all.
There's definitely room for debate here, so tell me if you think others should have cracked this list.
#LCSM